Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study
Kidney Research and Clinical Practice
; : 48-57, 2017.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-224474
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND:
Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients.METHODS:
CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years).RESULTS:
The median CAP value was 239 (202–274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38–706] vs. 56 [16–408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4–28.2] vs. 1.7 [0.6–9.9] mg/L, P < 0.001), and CAP (248 [210–302] vs. 226 [196–259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = −0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009–1.183; P = 0.029) even after adjusting for multiple confounding factors.CONCLUSION:
Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Triglicerídeos
/
Bilirrubina
/
Proteína C-Reativa
/
Albumina Sérica
/
Índice de Massa Corporal
/
Modelos Lineares
/
Modelos Logísticos
/
Razão de Chances
/
Diabetes Mellitus
/
Alanina Transaminase
Tipo de estudo:
Estudo diagnóstico
/
Estudo de etiologia
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Kidney Research and Clinical Practice
Ano de publicação:
2017
Tipo de documento:
Artigo